Royalty Pharma plc - Common Stock (RPRX)

Historical Holders from Q1 2019 to Q3 2025

Symbol
RPRX on Nasdaq
CUSIP
G7709Q104
Type / Class
Equity / Common Stock
Shares outstanding
432M
All holders as of September 30, 2025
Q3 2025
Total 13F shares, excl. options
328M
Holdings value
$11.6B
% of all portfolios
0.01%
Grand Portfolio weight change
-0.001%
Number of holders
476
Number of buys
286
Number of sells
-180
Average Value change %
+0%
Average buys %
+0.004%
Average sells %
-0.001%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Royalty Pharma plc - Common Stock (RPRX)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
Legorreta Pablo G. 19.74% $3.37B 103M Legorreta G. Pablo May 16, 2025
MORGAN STANLEY 9.2% $1.29B 38.9M Morgan Stanley Jun 30, 2025
Severgnini Achille G. 6.9% -17.5% $956M -$194M 29.9M -16.9% Severgnini Achille G. Apr 30, 2025
Capital International Investors 6.6% +18.3% $1.01B $191M 28.5M +23.4% Capital International Investors Sep 30, 2025
FMR LLC 6.5% -28.9% $984M -$400M 27.9M -28.9% FMR LLC Sep 30, 2025
BlackRock, Inc. 5.7% $813M 25.4M BlackRock, Inc. Dec 31, 2024
GENERAL ATLANTIC, L.P. 3.2% $525M 14.2M General Atlantic, L.P. Jun 30, 2025
VANGUARD GROUP INC 2.52% $386M 10.9M The Vanguard Group Sep 30, 2025

Institutional Holders of Royalty Pharma plc - Common Stock (RPRX)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 328M $11.6B -$521M $35.28 476
2025 Q2 342M $12.3B +$951M $36.03 450
2025 Q1 317M $9.86B -$38M $31.13 442
2024 Q4 320M $8.18B +$265M $25.51 411
2024 Q3 307M $8.68B -$212M $28.29 389
2024 Q2 316M $8.33B +$242M $26.37 373
2024 Q1 307M $9.33B +$5.41M $30.37 371
2023 Q4 6.09M $171M +$24.4M $28.09 7
2023 Q3 244M $6.62B -$572M $27.14 305
2023 Q2 246M $7.55B -$136M $30.74 313
2023 Q1 298M $10.7B +$36.5M $36.03 325
2022 Q4 297M $11.7B +$80.3M $39.52 326
2022 Q3 292M $11.7B +$249M $40.18 299
2022 Q2 286M $12B +$880M $42.04 272
2022 Q1 264M $10.3B +$68.2M $38.96 264
2021 Q4 265M $10.6B +$210M $39.85 249
2021 Q3 261M $9.42B +$494M $36.14 221
2021 Q2 248M $10.2B +$90.9M $40.99 225
2021 Q1 245M $10.7B +$826M $43.62 204
2020 Q4 225M $11.3B +$1.96B $50.05 183
2020 Q3 155M $6.5B +$401M $42.07 128
2020 Q2 146M $7.03B +$7.03B $48.55 118
2020 Q1 15 $1K $0 $66.67 1
2019 Q4 15 $1K $0 $66.67 1
2019 Q3 15 $1K $0 $66.67 1
2019 Q2 15 $1K $0 $66.67 1
2019 Q1 15 $1K $0 $66.67 1